EGFR and non-small cell lung carcinoma: Park et al. analyzed 217 patients with NSCLC who had received gemcitabine- or taxane-based chemotherapy, and found that taxane was associated with a higher response than gemcitabine treatment in patients with EGFR mutations [9].